{"id":61401,"date":"2026-03-26T15:09:32","date_gmt":"2026-03-26T07:09:32","guid":{"rendered":"https:\/\/flcube.com\/?p=61401"},"modified":"2026-03-26T15:09:33","modified_gmt":"2026-03-26T07:09:33","slug":"msd-to-acquire-terns-pharmaceuticals-for-6-7-billion-tern-701-bcrabl1-inhibitor-targets-chronic-myeloid-leukemia","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=61401","title":{"rendered":"MSD to Acquire Terns Pharmaceuticals for $6.7 Billion \u2013 TERN-701 BCR::ABL1 Inhibitor Targets Chronic Myeloid Leukemia"},"content":{"rendered":"\n

Merck & Co., Inc. (MSD; NYSE: MRK<\/a>)<\/strong> announced a definitive agreement<\/strong> to acquire Terns Pharmaceuticals, Inc. (NASDAQ: TERN<\/a>)<\/strong> for $53.00 per share in cash<\/strong>, representing an approximate equity value of $6.7 billion<\/strong> ($5.7 billion net of acquired cash). The transaction, expected to close Q3 2026<\/strong>, adds TERN-701<\/strong>, an investigational oral allosteric BCR::ABL1 tyrosine kinase inhibitor (TKI)<\/strong>, to Merck’s expanding hematology franchise<\/strong>, with potential to become a best-in-class therapy for chronic myeloid leukemia (CML)<\/strong> patients with treatment failure, suboptimal response, or intolerance to prior TKIs<\/strong>.<\/p>\n\n\n\n

Transaction Overview<\/h2>\n\n\n\n
Element<\/th>Detail<\/th><\/tr><\/thead>
Acquirer<\/strong><\/td>Merck & Co., Inc. (MSD; NYSE: MRK)<\/td><\/tr>
Target<\/strong><\/td>Terns Pharmaceuticals, Inc. (NASDAQ: TERN)<\/td><\/tr>
Purchase Price<\/strong><\/td>$53.00 per share cash<\/strong><\/td><\/tr>
Equity Value<\/strong><\/td>~$6.7 billion<\/strong><\/td><\/tr>
Net Transaction Value<\/strong><\/td>~$5.7 billion<\/strong> (after acquired cash)<\/td><\/tr>
Expected Closing<\/strong><\/td>Q3 2026 (subject to regulatory approvals)<\/td><\/tr>
Strategic Rationale<\/strong><\/td>Expand hematology presence; acquire best-in-class CML TKI<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

TERN-701 Asset Profile<\/h2>\n\n\n\n
Attribute<\/th>TERN-701 Specification<\/th><\/tr><\/thead>
Mechanism<\/strong><\/td>Oral allosteric BCR::ABL1 tyrosine kinase inhibitor (TKI)<\/strong><\/td><\/tr>
Target<\/strong><\/td>BCR::ABL1 fusion protein (Philadelphia chromosome-positive CML driver)<\/td><\/tr>
Differentiation<\/strong><\/td>Allosteric (non-ATP competitive) binding<\/strong> \u2013 distinct from ATP-site TKIs (imatinib, nilotinib, ponatinib)<\/td><\/tr>
Clinical Trial<\/strong><\/td>CARDINAL (NCT06163430)<\/strong> \u2013 Phase I\/II in Ph+ CML-CP<\/td><\/tr>
Patient Population<\/strong><\/td>Prior TKI failure, suboptimal response, or intolerance<\/td><\/tr>
FDA Designation<\/strong><\/td>Orphan Drug Designation (March 2024)<\/strong> \u2013 CML indication<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Context & Competitive Position<\/h2>\n\n\n\n
Factor<\/th>Implication<\/th><\/tr><\/thead>
CML Market Landscape<\/strong><\/td>~$5 billion globally<\/strong>; dominated by imatinib generics, nilotinib, ponatinib<\/strong>; resistance\/intolerance<\/strong> affects 30\u201340% of patients \u2013 significant unmet need<\/td><\/tr>
Allosteric TKI Advantage<\/strong><\/td>TERN-701’s novel binding site<\/strong> may overcome ATP-site resistance mutations<\/strong> (T315I, F317L) and reduce off-target toxicity<\/strong> vs. ponatinib<\/td><\/tr>
Merck Hematology Build<\/strong><\/td>Complements Winrevair (sotatercept)<\/strong> in pulmonary hypertension; establishes oncology-hematology<\/strong> presence beyond Keytruda immuno-oncology dominance<\/td><\/tr>
Best-in-Class Potential<\/strong><\/td>Robert M. Davis (CEO) explicit positioning vs. asciminib (Novartis)<\/strong> \u2013 only other allosteric BCR::ABL1 inhibitor approved; TERN-701 seeks superior efficacy\/safety profile<\/strong><\/td><\/tr>
Commercial Synergy<\/strong><\/td>Merck’s global oncology sales force<\/strong> (Keytruda infrastructure) accelerates TERN-701 launch vs. Terns standalone buildout<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n